Defining the genetic architecture of IBD in Ashkenazi Jewish populations

定义德系犹太人群体中 IBD 的遗传结构

基本信息

  • 批准号:
    8371995
  • 负责人:
  • 金额:
    $ 52.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The inflammatory bowel diseases (IBD) are comprised of Crohn's disease and ulcerative colitis and affect approximately 1.4 million Americans. A central feature of IBD epidemiology is the 4.3-7.7 fold increased prevalence of disease in Ashkenazi Jewish populations. It is unknown at present what factors account for this higher disease prevalence. This proposal will address this gap through testing two hypotheses. First, we hypothesize that uncommon variation of higher effects not well assayed by present genome-wide association study (GWAS) platforms contributes to IBD in Ashkenazi Jewish populations. An alternative hypothesis is that positive selection in the Ashkenazim, possibly involving a functional network of multiple loci involving common alleles, significantly contributes to the higher disease prevalence. Preliminary data are provided detailing a) the genetic architecture of IBD, with the unique absence of a dominant major histocompatibility complex in Crohn's disease, b) the precise nature of the population substructure between Jewish and non-Jewish European ancestry cohort, c) results of a genome-wide association study in Ashkenazi Jewish Crohn's disease which demonstrate a largely similar genetic architecture for common alleles, d) exome sequencing results in Jewish Crohn's disease cases, demonstrating the presence of uncommon alleles unique to the Ashkenazim, e) the present inadequacy of present reference sequences in critical immunoregulatory regions such as the KIR region on chromosome 19p13, f) enrichment of immune-mediated association signals in Th17-enriched cell subsets, and g) the improved molecular resolution achieved through RNASeq. A complete exploration of the underlying etiology for the markedly increased IBD prevalence in the Ashkenazim will be achieved through the interrogation of uncommon SNPs in the exome and throughout the genome through case control studies (Specific Aim 1). Important in this regard will be the ascertainment of large case-control cohorts, for which additional recruitment is proposed. The presence of uncommon risk alleles in the Ashkenazim might result from genetic drift, given their unique population history. An alternate possibility is that positive selection wthin the Ashkenazim at multiple loci, acting as a functional module, increases risk for IBD, and contributes to the higher disease prevalence compared to non-Jewish European ancestry cohorts. Refined definitions of associated alleles through regression analysis and functional annotation, together with interrogation of weaker effect alleles, will result in an aggregate estimate of the extent to which identified susceptibility alleles account for the higher disease prevalence in the Ashkenazim (Specific Aim 2). As with heritability, these estimates will provide a key measure of assessing the completeness of identified genetic factors in defining disease pathophysiology. PUBLIC HEALTH RELEVANCE: Defining the genetic factors that are associated to inflammatory bowel disease will help define the earliest steps in disease development. A major pathophysiologic clue to disease pathogenesis is the several-fold higher disease prevalence in the Ashkenazi Jewish population. This proposal outlines several complementary approaches to fully leverage unique features of this population to define mechanisms of disease pathogenesis. Identifying these early factors thoroughly will assist ultimately with the development of improved therapies.
描述(由申请人提供):炎症性肠病(IBD)由克罗恩病和溃疡性结肠炎组成,影响约140万美国人。IBD流行病学的一个中心特征是德系犹太人的患病率增加了4.3-7.7倍。目前尚不清楚是什么因素导致了这种较高的发病率。本提案将通过测试两个假设来解决这一差距。首先,我们假设,目前的全基因组关联研究(GWAS)平台没有很好地分析高影响的罕见变异导致了德系犹太人的IBD。另一种假设是,德系犹太人的正选择,可能涉及涉及共同等位基因的多个位点的功能网络,显著贡献

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JUDY H. CHO其他文献

JUDY H. CHO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JUDY H. CHO', 18)}}的其他基金

Intestinal single cell analyses and population differences in innate immunity in Crohn's disease drive treatment response and clinical heterogeneity: towards Precision IBD
肠道单细胞分析和克罗恩病先天免疫的群体差异驱动治疗反应和临床异质性:迈向精准 IBD
  • 批准号:
    9893616
  • 财政年份:
    2020
  • 资助金额:
    $ 52.61万
  • 项目类别:
Intestinal single cell analyses and population differences in innate immunity in Crohn's disease drive treatment response and clinical heterogeneity: towards Precision IBD
肠道单细胞分析和克罗恩病先天免疫的群体差异驱动治疗反应和临床异质性:迈向精准 IBD
  • 批准号:
    10339391
  • 财政年份:
    2020
  • 资助金额:
    $ 52.61万
  • 项目类别:
Intestinal single cell analyses and population differences in innate immunity in Crohn's disease drive treatment response and clinical heterogeneity: towards Precision IBD
肠道单细胞分析和克罗恩病先天免疫的群体差异驱动治疗反应和临床异质性:迈向精准 IBD
  • 批准号:
    10580608
  • 财政年份:
    2020
  • 资助金额:
    $ 52.61万
  • 项目类别:
Integrative Genomic Analyses of Macrophages in Crohns Disease
克罗恩病巨噬细胞的综合基因组分析
  • 批准号:
    9767134
  • 财政年份:
    2016
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining the genetic architecture of IBD in Ashkenazi Jewish populations
定义德系犹太人群体中 IBD 的遗传结构
  • 批准号:
    8688235
  • 财政年份:
    2012
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining the genetic architecture of IBD in Ashkenazi Jewish populations
定义德系犹太人群体中 IBD 的遗传结构
  • 批准号:
    8867806
  • 财政年份:
    2012
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining the genetic architecture of IBD in Ashkenazi Jewish populations
定义德系犹太人群体中 IBD 的遗传结构
  • 批准号:
    8537920
  • 财政年份:
    2012
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining the genetic architecture of IBD in Ashkenazi Jewish populations
定义德系犹太人群体中 IBD 的遗传结构
  • 批准号:
    8913947
  • 财政年份:
    2012
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining the genetic architecture of IBD in Ashkenazi Jewish populations
定义德系犹太人群体中 IBD 的遗传结构
  • 批准号:
    9094680
  • 财政年份:
    2012
  • 资助金额:
    $ 52.61万
  • 项目类别:
Beyond single-point GWAS: genetics of Crohn's disease in Ashkenazi Jews
超越单点 GWAS:德系犹太人克罗恩病的遗传学
  • 批准号:
    7819964
  • 财政年份:
    2009
  • 资助金额:
    $ 52.61万
  • 项目类别:

相似国自然基金

19q13重叠基因可变剪接在多环芳烃类环境污染物致肺癌变中的特征及意义
  • 批准号:
    81773470
  • 批准年份:
    2017
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目
基于染色体19q13区域miRNA的表达研究新型多酚化合物BJA3121抗肿瘤细胞增殖作用的分子靶点
  • 批准号:
    30901823
  • 批准年份:
    2009
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Variation of the NK Cell Receptome in Pemphigus
天疱疮NK细胞受体组的变异
  • 批准号:
    10750358
  • 财政年份:
    2023
  • 资助金额:
    $ 52.61万
  • 项目类别:
Uncovering novel mechanisms and potential therapeutic targets for IgA vasculitis through GWAS and systems-level analysis of regulatory networks.
通过 GWAS 和调节网络的系统级分析揭示 IgA 血管炎的新机制和潜在治疗靶点。
  • 批准号:
    10723651
  • 财政年份:
    2023
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining Variation in the Natural Killer Cell Receptome in Human Populations
定义人类自然杀伤细胞受体组的变异
  • 批准号:
    10430920
  • 财政年份:
    2022
  • 资助金额:
    $ 52.61万
  • 项目类别:
Defining Variation in the Natural Killer Cell Receptome in Human Populations
定义人类自然杀伤细胞受体组的变异
  • 批准号:
    10686403
  • 财政年份:
    2022
  • 资助金额:
    $ 52.61万
  • 项目类别:
Characterizing the Takayasu arteritis genetic risk in RPS9/LILRB3
RPS9/LILRB3 中大动脉炎遗传风险的表征
  • 批准号:
    10017651
  • 财政年份:
    2019
  • 资助金额:
    $ 52.61万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    9914435
  • 财政年份:
    2019
  • 资助金额:
    $ 52.61万
  • 项目类别:
ApoE2 and protective molecular signatures in Alzheimer's disease and aging
ApoE2 和阿尔茨海默病和衰老中的保护性分子特征
  • 批准号:
    10425329
  • 财政年份:
    2018
  • 资助金额:
    $ 52.61万
  • 项目类别:
ApoE2 and protective molecular signatures in Alzheimer's disease and aging
ApoE2 和阿尔茨海默病和衰老中的保护性分子特征
  • 批准号:
    10170216
  • 财政年份:
    2018
  • 资助金额:
    $ 52.61万
  • 项目类别:
Characterizing the Takayasu Arteritis Genetic Risk in RPS9/LILRB3
RPS9/LILRB3 中大动脉炎遗传风险的表征
  • 批准号:
    9308409
  • 财政年份:
    2017
  • 资助金额:
    $ 52.61万
  • 项目类别:
Computational methods for detecting patterns of complex genomic variation
检测复杂基因组变异模式的计算方法
  • 批准号:
    9198242
  • 财政年份:
    2016
  • 资助金额:
    $ 52.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了